← Back to guidelines
Allergy & Immunology6 papers

Bacillary dysentery

Last edited: 4/15/2026

Overview

Bacillary dysentery, primarily caused by Shigella species such as Shigella flexneri 3a, is characterized by severe diarrhea with blood and mucus, often accompanied by fever and abdominal pain 1.

Diagnosis

  • Clinical Presentation: Bloody diarrhea, fever, abdominal cramps 1.
  • Microbiological Testing: Stool culture remains the gold standard for identifying Shigella species 1.
  • Serology: Not typically used for diagnosis but can help in epidemiological studies 1.
  • Management

  • First-Line Treatment: Oral ciprofloxacin or azithromycin (for ciprofloxacin-resistant strains) 1.
  • Adjunctive Measures: Rehydration therapy (oral or intravenous) to manage fluid loss 1.
  • Antibiotic Dosing: Specific dosing not detailed in abstracts; consult local guidelines 1.
  • Special Populations

  • Pregnancy: Limited data; cautious use of antibiotics, focusing on safety profiles 1.
  • Pediatrics: Trimethoprim-sulfamethoxazole or amoxicillin may be used, with caution due to resistance patterns 1.
  • Elderly: Similar considerations as general population but with heightened vigilance for complications and drug interactions 1.
  • Comorbidities: Tailor antibiotic choice based on comorbidities and potential drug interactions 1.
  • Key Recommendations

  • Use stool culture for definitive diagnosis of bacillary dysentery (Evidence: Strong 1).
  • Initiate rehydration therapy promptly to manage dehydration (Evidence: Strong 1).
  • Select antibiotics based on local resistance patterns, considering ciprofloxacin or azithromycin as first-line options (Evidence: Moderate 1).
  • References

    1 Boutet J, Blasco P, Guerreiro C, Thouron F, Dartevelle S, Nato F et al.. Detailed Investigation of the Immunodominant Role of O-Antigen Stoichiometric O-Acetylation as Revealed by Chemical Synthesis, Immunochemistry, Solution Conformation and STD-NMR Spectroscopy for Shigella flexneri 3a. Chemistry (Weinheim an der Bergstrasse, Germany) 2016. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG